GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Statistically significant and clinically meaningful improvements in heart failure-related health status, measured by the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS ...

Lilly's drug also significantly improved heart failure symptoms and physical limitations measured using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) compared to ...

Participants taking tirzepatide also had a better average Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) than the placebo group, showing a significant improvement in ...

Statistically significant and clinically meaningful improvements in heart failure-related health status, measured by the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS), ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...